China Accepts InnoCare’s Orelabrutinib Application for ITP Treatment

PUBT · 1d ago
China Accepts InnoCare’s Orelabrutinib Application for ITP Treatment
  • China accepted InnoCare Pharma's new drug application for orelabrutinib to treat chronic primary immune thrombocytopenia.
  • The acceptance marks the drug's first application in autoimmune diseases, expanding its potential use beyond hematologic malignancies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050534PRIMZONEFULLFEED9871114) on November 05, 2026, and is solely responsible for the information contained therein.